Topiramate and its clinical applications in epilepsy

Bibliography

• HAUSER WA, ANNEGERS JF, KURLAND LT: Prevalence of epilepsy in Rochester, Minnesota: 1940 – 1980. Epilepsia (1991) 32:429-445.
   PubMed Web of Science ®Google Scholar
• HAUSER WA, ANNEGERS JF, KURLAND LT: Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935 – 1984. Epilepsia (1993) 34:453-468.
   PubMed Web of Science ®Google Scholar
• SANDER JW: Some aspects of prognosis in epilepsy. A review. Epilepsia (1993) 34:1007-1016.
   PubMed Web of Science ®Google Scholar
• BRODIE MJ: Diagnosing and predicting refractory epilepsy. Acta Neurol. Scand. (2005) 112:36-39.
   PubMed Web of Science ®Google Scholar
• SPERLING M: The consequences of uncontrolled epilepsy. CNS Spectr. (2004) 9:98- 101, 106-109.
   PubMed Web of Science ®Google Scholar
• SHANK RP, GARDOCKI JF, VAUGHT JL et al.: Topiramate: preclinical evaluation of structurally novel anticonvulsant. Epilepsia (1994) 35:450-460.
   PubMed Web of Science ®Google Scholar
• WHITE HS, WOODHEAD J, WOLF HH: Effect of topiramate (TPM) on pentylenetetrazol (PZT) Seizure threshold. Epilepsia (1996) 37(Suppl. 5):S26.
   Google Scholar
• NAKAMURA J, TAMURA S, KANDA T et al.: Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice. Eur. J. Pharmacol. (1994) 254:83-89.
   PubMed Web of Science ®Google Scholar
• WAUQUIER A, ZHOU S: Topiramate: a potent anticonvulsant in the amygdala-kindled rat. Epilepsy Res. (1996) 24:73-77.
   PubMed Web of Science ®Google Scholar
• REISSMULLER E, EBERT U, LOSCHER W: Anticonvulsant efficacy of topiramate in phenytoin-resistant kindled rats. Epilpesia (2000) 41:372-329.
   PubMed Web of Science ®Google Scholar
• SHANK RP, GARDOCKI JF, VAUGHT JL et al.: Topiramate: preclinical evaluation of structurally novel anticonvulsant. Epilepsia (1994) 35:450-460.
   Google Scholar
• COULTER DA, SOMBATI S, DE LORENZO RJ: Selective effects of topiramate on sustained repetitive firing and spontaneous busting in cultured hippocampal neurons. Epilepsia (1993) 34(Suppl. 2):S123.
   Google Scholar
• SOMBATI S, COULTER DA, DE LORENZO RJ: Effects of topiramate on sustained repetitive firing and low Mg2+-induced Seizure discharges in cultured hippocampal neurons. Epilepsia (1995) 36(Suppl. 4):S38.
   Google Scholar
• ZONA C, CIOTTI MT, AVOLI M: Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci. Lett. (1997) 231:123-126.
   PubMed Web of Science ®Google Scholar
• WU SP, TSAI JJ, GEAN PW: Frequency-dependant inhibition of neuronal activity by topiramate in rat hippocampal slices. Br. J. Pharmacol. (1998) 125:826-832.
   PubMed Web of Science ®Google Scholar
• TAVERNA S, SANCINI G, MANTEGAZZA M, FRANCESCHETTI S, AVANZINI G: Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate. J. Pharmacol. Exp. Ther. (1999) 288:960-968.
   PubMed Web of Science ®Google Scholar
• WHITE HS, BROWN SD, WOODHEAD JH, SKEEN GA, WOLF HH: Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res. (1997) 28:167-179.
   PubMed Web of Science ®Google Scholar
• WHITE HS, BROWN D, SKEEN GA et al.: The anticonvulsant topiramate displays a unique ability to potentiate GABA-evoked chloride currents. Epilepsia (1995) 36(Suppl. 3):S39-S40.
   Google Scholar
• GORDEY M, DELOREY TM, OLSEN RW: Differential sensitivity of recombinant GABAA receptors expressed in Xenopus oocytes to modulation by topiramate. Epilepsia (2000) 41(Suppl. 1):S25-S29.
   PubMedGoogle Scholar
• SEVERT L, COULTER DA, SOMBATI S, DE LORENZO RJ: Topiramate selectively blocks kainate currents in cultured hippocampal neurons. Epilepsia (1995) 36(Suppl. 4):S38.
   Google Scholar
• COULTER DA, SOMBATI S, DE LORENZO RJ: Topiramate effects on excitatory amino acid-mediated responses in cultured hippocampal neurons: selective blockade of kainate currents. Epilepsia (1995) 32(Suppl. 3):19.
   Google Scholar
• SKRADSKI S, WHITE HS: Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia (2000) 41(Suppl. 1):S45-S47.
   PubMed Web of Science ®Google Scholar
• ZHANG X, VELUMIAN AA, JONES OT, CARLEN PL: Topiramate reduces high-voltage activated Ca2+ currents in CA1 pyramidal neurons in vitro. Epilepsia (1998) 39(Suppl. 6):S44.
   Google Scholar
• ZHANG X, VELUMIAN AA, JONES OT, CARLEN PL: Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia (2000) 41(Suppl.1):S52-S60.
   Google Scholar
• HASSAN H, GRECKSCH G, RUTHRICH H, KRUG M: Effects of nicardipine, an antagonist of -type voltage-dependent calcium channels, on kindling development, kindling-induced learning deficits and hippocampal potentiation phenomena. Neuropharmacology (1999) 38:1841-1850.
   PubMed Web of Science ®Google Scholar
• IKEGAYA Y, NISHIYAMA N, MATSUKI N: L-type Ca2+ channel blocker inhibits mossy fiber sprouting and cognitive deficits following pilocarpine seizures in immature mice. Neuroscience (2000) 98:647-659.
   PubMed Web of Science ®Google Scholar
• VAN LUIJTELAAR EL, ATES N, COENEN AM: Role of L-type calcium channel modulation in nonconvulsive epilepsy in rats. Epilpesia. (1995) 36:86-92.
   PubMed Web of Science ®Google Scholar
• HERRERO AI, DEL OLMOA N, GONZÁLEZ-ESCALADAB JR, SOLÍS JM: Two new actions of topiramate: inhibition of depolarizing GABAA-mediated responses and activation of a potassium conductance. Neuropharmacology (2002) 42:210-220.
   PubMed Web of Science ®Google Scholar
• SINGH NA, WESTENSKOW P, CHARLIER C et al.: KCNQ2 and KCNQ3 potassium channel genes in benign familial neonatal convulsions: expansion of the functional and mutation spectrum. Brain (2003) 126:2726-2737.
   PubMed Web of Science ®Google Scholar
• DODGSON SJ, SHANK RP, MARYANOFF BE: Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia (2000) 41(Suppl. 1):S35-S39.
   PubMed Web of Science ®Google Scholar
• RHO JM, SANKAR R: The pharmacologic basis of antiepileptic drug action. Epilepsia (1999) 40:1471-1483.
   PubMed Web of Science ®Google Scholar
• SCHWRTZKROIN PA: Cellular electrophysiology of human epilepsy. Epilepsy Res. (1994) 17:185-192.
   PubMed Web of Science ®Google Scholar
• TRAYNELIS SF, CULL-CANDY SG: Proton inhibition of N-methyl-D-aspartate receptors in cerebellar neurons. Nature (1990) 345:347-350.
   PubMed Web of Science ®Google Scholar
• KRISHEK BJ, AMATO A, CONNOLLY CN, MOSS SJ, SMART TG: Proton sensitivity of the GABAA receptors is associated with the receptor subunit composition. J. Physiol. (1996) 492:431-443.
   PubMed Web of Science ®Google Scholar
• GIBBS JW III, SOMBATI S, DE LORENZO RJ, COULTER DA: Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia (2000) 41(Suppl. 1):S10-S16.
   PubMed Web of Science ®Google Scholar
• ÄNGEHAGEN M, BEN-MENACHEM E, SHANK R, RONNBACK L, HANSSON E: Topiramate modulation of kainate-induced calcium currents is inversely related to channel phosphorylation level. J. Neurochem. (2004) 88:320-325.
   PubMed Web of Science ®Google Scholar
• DOOSE DR, WALKER SA, GISCLON LG, NAYAK RK: Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. J. Clin. Pharmacol. (1996) 36:884-891.
   PubMed Web of Science ®Google Scholar
• NAYAK RK, GISCLON LG, CURTIN CA et al.: Estimation of the absolute bioavailability of topiramate in humans without intravenous data. J. Clin. Pharmacol. (1994) 34:1029.
   Google Scholar
• WU WN, HEEBNER JB, STREETER AJ et al.: Evaluation of the absorption, excretion, pharmacokinetics and metabolism of the anticonvulsant topiramate in healthy men. Pharm. Res. (1994) 11:S336.
   Google Scholar
• CONWAY JM, BIRNBAUM AK, KRIEL RL, CLOYD JC: Relative bioavailability of topiramate administered rectally. Epilepsy Res. (2003) 54:91-96.
   PubMed Web of Science ®Google Scholar
• DOOSE DR, GLISCLON LG, LIAO S, WU WN: Pharmacokinetics of topiramate. Adv. Antiepil. Drug Ther. (1995) 1:7-16.
   Google Scholar
• DOOSE DR, STREETER AJ: Topiramate. Chemistry, biotransformation and pharmacokinetics. In: Antiepileptic Drugs (5th Edition). RH Levy, RH Mattson, BS Meldrum, Perucca E (Eds), Williams & Wilkins, Philadelphia, PA, USA (2002):727-734.
   Google Scholar
• PERUCCA E: A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol. Res. (1997) 35:241-256.
   PubMed Web of Science ®Google Scholar
• ÖHMAN I, VITOLS S, LUEF G, SÖDERFELDT B, TOMSON T: Topiramate kinetics during delivery, lactation, and in the neonate: preliminary observations. Epilepsia (2002) 43:1157-1160.
   PubMed Web of Science ®Google Scholar
• PRIVITERA MD, TWYMAN RE: Topiramate. Clinical efficacy and use in epilepsy. In: Antiepileptic Drugs (5th Edition). RHLevy, RH Mattson, BS Meldrum, E Perucca (Eds), Williams & Wilkins, Philadelphia, PA, USA (2002):740-752.
   Google Scholar
• SAMREN EB, VAN DUIJN CM, CHRISTIAENS CG, HOFMAN A, LINDHOUT D: Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann. Neurol. (1999) 46:739-746.
   PubMed Web of Science ®Google Scholar
• HOLMES LB, WYSZYNSKI DF: North American antiepileptic drug pregnancy registry. Epilepsia (2004) 45:1465.
   PubMed Web of Science ®Google Scholar
• TORBJORN T, BATTINO D, BONIZZONI E et al.: EURAP: an international registry of antiepileptic drugs and pregnancy. Epilepsia (2004) 45:1463-1464.
   PubMed Web of Science ®Google Scholar
• NORTEY SO, WU WN, MARYANOFF BE: Synthesis of hydroxylated derivatives of topiramate, a novel antiepileptic drug based on D-fructose: investigation of oxidative metabolites. Carbohydr. Res. (1997) 304:29-38.
   PubMed Web of Science ®Google Scholar
• GISCLON LG, RIFFITS JM, SICA DA: The pharmacokinetics of topiramate in subjects with renal impairment as compared to matched subjects with normal renal function. Pharm. Res. (1993) 10(Suppl.):S397.
   Google Scholar
• FERRARI AR, GUERRINI R, GATTI G, ALESSANDRI MG, BONANNI P, PERUCCA E: Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. Ther. Drug Monit. (2003) 25:700-708.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN J, ANDREASEN F, POULSEN JH, DAM M: Randomized, concentration-controlled trial of topiramate in refractory focal epilepsy. Neurology (2003) 61:1210-1218.
   PubMed Web of Science ®Google Scholar
• DOOSE DR, SCOTT VV, MARGUL BL, MARRIOTT TB, NAYAK RK: Multiple-dose pharmacokinetics of topiramate in healthy male subjects. Epilepsia (1988) 29:662. Abstract.
   Google Scholar
• EASTERLING DE, ZAKSZEWSKIN T, MOYER MD, MARGUL BL, MARRIOTT TB, NAYAK RK: Plasma pharmacokinetics of topiramate, a new anticonvulsant, in humans. Epilepsia (1988) 29:662. Abstract.
   Web of Science ®Google Scholar
• ROSENFELD WE, DOOSE DR, WALKER SA, BALDASSARRE JS, REIFE RA: A study of topiramate pharmacokinetics and tolerability in children with epilepsy. Pediatr. Neurol. (1999) 20:339-344.
   PubMed Web of Science ®Google Scholar
• ADIN J, GOMEZ MC, BLANCO Y, HERRANZ JL, ARMIJO JA: Topiramate serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and monitoring implications. Ther. Drug Monit. (2004) 26:251-257.
   PubMed Web of Science ®Google Scholar
• DOOSE DR, LARSON KL, NATARAJAN J et al.: Comparative single-dose pharmacokineitcs of topiramate in elderly versus young men and women. Epilepsia (1999) 39(Suppl. 6):56 (Abstract).
   Google Scholar
• LEVY RH, BISHOP F, STREETER AJ et al.: Explanation and prediction of drug interaction with topiramate using CYP450 inhibition spectrum. Epilepsia (1995) 36(Suppl.4):S47 (Abstract).
   Web of Science ®Google Scholar
• SACHDEO RC, SACHDEO SK, LEVY RH et al.: Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia (2002) 43:691-696.
   PubMed Web of Science ®Google Scholar
• WILENSKY AJ, OJEMANN LM, CHMELIR T et al.: Topiramate pharmacokinetics in epileptic patients receiving carbamazepine. Epilepsia (1989) 30:645 (Abstract).
   Google Scholar
• ROSENFELD WE, LIAO S, KRAMER LD et al.: Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilpesia. (1997) 38:324-333.
   PubMed Web of Science ®Google Scholar
• HAMER HM, KNAKE S, SCHOMBURG U, ROSENOW F: Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology (2000) 54:230-232.
   PubMed Web of Science ®Google Scholar
• WNUK W, VOLANSKI A, FOLETTI G: Topiramate decrease lamotrigine concentrations. Ther. Drug Monit. (1999) 21:449-459.
   Google Scholar
• DOOSE DR, BRODIE MJ, WILSON EA et al.: Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. Epilepsia (2003) 44:917-922.
   PubMed Web of Science ®Google Scholar
• ROSENFELD WE, DOOSE DR, WALKER SA, NAYAK RK: Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilpesia. (1997) 38:317-323.
   PubMed Web of Science ®Google Scholar
• BEN-MENACHEM E, HENRIKSEN O, DAM M et al.: Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia (1996) 37:539-543.
   PubMed Web of Science ®Google Scholar
• FAUGHT E, WILDER BJ, RAMSAY RE et al.: Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group. Neurology (1996) 46:1684-1690.
   PubMed Web of Science ®Google Scholar
• PRIVITERA M, FINCHAM R, PENRY J et al.: Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group. Neurology (1996) 46:1678-1683.
   PubMed Web of Science ®Google Scholar
• ROSENFELD W, ABOU-KHALIL B, MORRELL M et al.: Double-blind placebo controlled trial of topiramate adjunctive therapy for partial onset epilepsy. Epilepsia (1996) 37(Suppl. 4):S56.
   PubMed Web of Science ®Google Scholar
• SHARIEF M, VITERI C, BEN-MENACHEM E et al.: Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res. (1996) 25:217-224.
   PubMed Web of Science ®Google Scholar
• TASSINARI CA, MICHELUCCI R, CHAUVEL P et al.: Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia (1996) 37:763-768.
   PubMed Web of Science ®Google Scholar
• KOREAN TOPIRAMATE STUDY GROUP: Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial. Epilepsia (1999) 40:1767-1774.
   PubMed Web of Science ®Google Scholar
• YEN DJ, YU HY, GUO YC, CHEN C, YIU CH, SU MS: A double-blind, placebo-controlled study of topiramate in adult patients with refractory partial epilepsy. Epilepsia (2000) 41:1162-1166.
   PubMed Web of Science ®Google Scholar
• REIFE R, PLEDGER G, WU SC: Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia (2000) 41(Suppl. 1):S66-S71.
   PubMedGoogle Scholar
• GUBERMAN A, NETO W, GASSMANN-MAYER C; EPAJ-119 STUDY GROUP: Low-dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurol. Scand. (2002) 106:183-189.
   PubMed Web of Science ®Google Scholar
• ELTERMAN RD, GLAUSER TA, WYLLIE E, REIFE R, WU SC, PLEDGER G: A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Topiramate YP Study Group. Neurology (1999) 52:1338-1344.
   PubMed Web of Science ®Google Scholar
• RITTER F, GLAUSER TA, ELTERMAN RD, WYLLIE E: Effectiveness, tolerability, and safety of topiramate in children with partial-onset seizures. Topiramate YP Study Group. Epilepsia (2000) 41(Suppl. 1):S82-S85.
   PubMed Web of Science ®Google Scholar
• BITON V, MONTOURIS GD, RITTER F et al.: A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology (1999) 52:1330-1337.
   PubMed Web of Science ®Google Scholar
• GLAUSER TA, ELTERMAN R, WYLLIE E, TOPIRAMATE YP STUDY TEAM: Open-label topiramate in paeditric partial epilepsy. Epilepsia (1997) 38(Suppl. 3):S94.
   Google Scholar
• SACHDEO RC, GLAUSER TA, RITTER F, REIFE R, LIM P, PLEDGER G: A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology (1999) 52:1882-1887.
   PubMed Web of Science ®Google Scholar
• GLAUSER TA, LEVISOHN PM, RITTER F, SACHDEO RC: Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia (2000) 41(Suppl. 1):S86-S90.
   PubMedGoogle Scholar
• SACHDEO RC, REIFE RA, LIM P, PLEDGER G: Topiramate monotherapy for partial onset seizures. Epilepsia (1997) 38:294-300.
   PubMed Web of Science ®Google Scholar
• GILLIAM FG, VELOSO F, BOMHOF MAM et al.: A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology (2003) 60:196-202.
   PubMed Web of Science ®Google Scholar
• PRIVITERA MD, BRODIE MJ, MATTSON RH, CHADWICK DW, NETO W, WANG S FOR THE EPMN 105 STUDY GROUP: Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol. Scand. (2003) 107:165-175.
   PubMed Web of Science ®Google Scholar
• SACHDEO RC, PATEL R, REHMAN KU: Long-term experience with topiramate monotherapy. Epilepsia (1997) 38(Suppl.8):S97.
   Google Scholar
• WHELESS JW, NETO W, WANG S; EPMN-105 STUDY GROUP: Topiramate, carbamazepine, and valproate monotherapy: double-blind comparison in children with newly diagnosed epilepsy. J. Child Neurol. (2004) 19:135-141.
   PubMed Web of Science ®Google Scholar
• WANG Y, ZHOU D, PAULI E, STEFAN H: Topiramate on ictal semiology: a quantitative, randomised, low and medium dose-controlled study. Epilepsy Res. (2001) 46:271-277.
   PubMed Web of Science ®Google Scholar
• WANG Y, ZHOU D, WANG B et al.: Clinical effects of topiramate against secondary generalised tonic-clonic seizures. Epilepsy Res. (2002) 49:121-130.
   PubMed Web of Science ®Google Scholar
• ABOU-KHALIL B, TOPIRAMATE YOL STUDY GROUP: Topiramate in the long-term management of refractory epilepsy. Epilepsia (2000) 41(Suppl.1):S72-S76.
   PubMed Web of Science ®Google Scholar
• CANGER R, AVANZINI G, TARTARA A et al.: Long-term efficacy and tolerability of topiramate add-on therapy; interim analysis after four year treatment. Epilepsia (1997) 38(Suppl. 3):S59.
   Google Scholar
• MICHELUCCI R, PASSARELLI D, RIGUZZI P et al.: Long-term follow-up of TPM in refractory partial seizures. Epilepsia (1998) 39(Suppl. 2):S67.
   PubMed Web of Science ®Google Scholar
• ROSENFELD WE, SACHDEO RC, FAUGHT RE et al.: Long-term experience with topiramate as adjunctive therapy and as monotherapy in patients with partial onset seizure: retrospective survey of open-label treatment. Epilepsia (1997) 38(Suppl.1):S34-S36.
   Google Scholar
• STEPHEN LJ, SILLS GJ, BRODIE MJ: Topiramate in refractory epilepsy: a prospective observational study. Epilepsia (2000) 41:977-980.
   PubMed Web of Science ®Google Scholar
• MIKAELOFF Y, DE SAINT-MARTIN A, MANCINI J et al.: Topiramate: efficacy and tolerability in children according to epilepsy syndrome. Epilepsy Res. (2003) 53:225-232.
   PubMed Web of Science ®Google Scholar
• COPPOLA G, CAPOVILLA G, MONTAGNINI A et al.: Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Res. (2002) 49:45-48.
   PubMed Web of Science ®Google Scholar
• COPPOLA G, CALIENDO G, VEGGIOTTI P et al.: Topiramate as add-on drug in children, adolescent and young adults with Lennox-Gastaut syndrome: an Italian multicentric study. Epilepsy Res. (2002) 51:147-153.
   PubMed Web of Science ®Google Scholar
• GUERRINI R, CARPAY H, GROELJ J, VAN OENE J, LAHAYE M, SCHWALEN S, TOP-INT-51 INVESTIGATORS’ GROUP: Topiramate monotherapy as broad spectrum antiepileptic in naturalistic clinical setting. Seizure (2005) 14:371-380.
   PubMed Web of Science ®Google Scholar
• GLAUSER TA, CLARK PO, STRAWSBURG R: A pilot study of topiramate in the treatment of infantile spasms. Epilepsia (1998) 39:1324-1328.
   PubMed Web of Science ®Google Scholar
• GLAUSER TA, CLARK PO, MCGEE K: Long-term response to topiramate in patients with West syndrome. Epilepsia (2000) 41(Suppl. 1):S91-S94.
   PubMed Web of Science ®Google Scholar
• ROSENFELD WE, SCHAEFER PA, LIPPMANN SM: Topiramate in patients with juvenile myoclonic epilepsy. Epilepsia (1998) 39(Suppl. 6):139.
   Google Scholar
• CROSS JH: Topiramate monotherapy for childhood absence seizures: an open label pilot study. Seizure (2002) 11:406-410.
   PubMed Web of Science ®Google Scholar
• SINGH BK, WHITE-SCOTT S: Role of topiramate in adults with intractable epilepsy, mental retardation, and developmental disabilities. Seizure (2002) 11:47-50.
   PubMed Web of Science ®Google Scholar
• ARVIO M, SILLANPAÄ M: Topiramate in long-term treatment of epilepsy in intellectually disabled. J. Intellect. Disabil. Res. (2005) 49:183-189.
   PubMed Web of Science ®Google Scholar
• TOWNE AR, GARNETT RN, WATERHOUSE EJ, MORTON LD, DE LORENZO RJ: The use of topiramate in refractory status epilepticus. Neurology (2003) 60:332-334.
   PubMed Web of Science ®Google Scholar
• JETTE NJ, MARSON AG, HUTTON JL: Topiramate for drug-resistant partial epilepsy. Cochrane Database Syst. Rev. (2002) 3:CD001417.
   Google Scholar
• FRENCH JA, KANNER AM, BAUTISTA J et al.: Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Neurology (2004) 62:1252-1260.
   PubMed Web of Science ®Google Scholar
• FRENCH JA, KANNER AM, BAUTISTA J et al.: Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy. Neurology (2004) 62:1261-1273.
   PubMed Web of Science ®Google Scholar
• TATUM WO IV, FRENCH JA, FAUGHT E et al.: Postmarketing experience with topiramate and cognition. Epilepsia (2001) 42:1134-1140.
   PubMed Web of Science ®Google Scholar
• MEADOR KJ, LORING DW, HULIHAN JF, KAMIN M, KARIM R, CAPSS-027 STUDY GROUP: Differential cognitive and behavioural effects of topiramate and valproate. Neurology (2003) 60:1483-1488.
   PubMed Web of Science ®Google Scholar
• MARTIN R, KUZNIECKY R, HO S et al.: Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults. Neurology (1999) 52:321-327.
   PubMed Web of Science ®Google Scholar
• THOMPSON PJ, BAXENDALE SA, DUNCAN JS, SANDER JW: Effects of topiramate on cognitive function. J. Neurol. Neurosurg. Psychiatry (2000) 69:636-641.
   PubMed Web of Science ®Google Scholar
• LEE S, SZIKLAS V, ANDERMANN F et al.: The effects of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia (2003) 44:339-347.
   PubMed Web of Science ®Google Scholar
• GROSS-TSUR V, SHALEV RS: Reversible language regression as an adverse effect of topiramate treatment in children. Neurology (2004) 62:299-300.
   PubMed Web of Science ®Google Scholar
• CRAWFORD P: An audit of topiramate use in general neurology clinic. Seizure (1998) 7:207-211.
   PubMed Web of Science ®Google Scholar
• MULA M, TRIMBLE MR, LHATOO SD, SANDER JW: Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia (2003) 44:659-663.
   PubMed Web of Science ®Google Scholar
• LATOUR P, BIRABEN A, POLARD E et al.: Drug induced encephalopathy in six epileptic patients: topiramate? valproate? or both? Hum. Psychopharmacol. (2004) 19:193-203.
   PubMed Web of Science ®Google Scholar
• STEPHEN LJ, MAXWELL JE, BRODIE MJ: Drug points: transient hemiparesis with topiramate. Br. Med. J. (1999) 52:1338-1344.
   Google Scholar
• PATEL H, ASCONAPE JJ, GARG BP: Reversible hemiparesis associated with the use of topiramate. Seizure (2002) 11:460-463.
   PubMed Web of Science ®Google Scholar
• PARMEGGIANI L, SERI S, BONANNI P, GUERRINI R: Electrophysiological characterisation of spontaneous and carbamazepine-induced epileptic negative myoclonus in benign childhood epilepsy with centro temporal spikes. Clin. Neurophysiol. (2004) 115:50-58.
   PubMed Web of Science ®Google Scholar
• LAMB EJ, STEVENS PE, NASHEF L: Topiramate increases biochemical risk of nephrolithiasis. Ann. Clin. Biochem. (2004) 41:166-169.
   PubMed Web of Science ®Google Scholar
• SACHDEO RC, KARIA RM: Topiramate. Adverse effects. In: Antiepileptic drugs (5th Edition). RH Levy, RH Mattson, BS Meldrum, E Perucca (Eds), Lippincott, Williams & Wilkins, Philadelphia, PA, USA (2002):760-764.
   Google Scholar
• TAKEOKA M, HOLMES GL, THIELE E et al.: Topiramate and metabolic acidosis in paediatric epilepsy. Epilepsia (2001) 42:387-392.
   PubMed Web of Science ®Google Scholar
• FRAUNFELDER FW, FRAUNFELDER FT: Adverse ocular drug reactions recently identified by the National Registry of drug-induced ocular side effects. Ophthalmology (2004) 111:1275-1279.
   PubMed Web of Science ®Google Scholar
• BOENTERT M, ARETZ H, LUDERMANN P: Acute myopia and angle-closure glaucoma induced by topiramate. Neurology (2003) 61:1306.
   PubMed Web of Science ®Google Scholar
• CRAIG JE, ONG TJ, LOUIS DL, WELLS JM: Mechanism of topiramate-induced acute-onset myopia and angle closure glaucoma. Am. J. Ophthalmol. (2004) 137:193-195.
   PubMed Web of Science ®Google Scholar
• PHILIPPI H, BOOR R, REITTER B: Topiramate and metabolic acidosis in infants and toddlers. Epilepsia (2002) 43:744-747.
   PubMed Web of Science ®Google Scholar
• SHETH RD: Metabolic concerns associated with antiepileptic medications. Neurology (2004) 63:S24-S29.
   PubMedGoogle Scholar
• YORK DA, SINGER L, THOMAS S, BRAY GA: Effect of topiramate on body weight and body composition of osborne-mendel rats fed a high-fat diet: alterations in hormones, neuropeptide, and uncoupling-protein mRNAs. Nutrition (2000) 16:967-975.
   PubMed Web of Science ®Google Scholar
• ARCAS J, FERRER T, ROCHE MC, MARTINEZ-BERMEJO A, LOPEZ-MARTIN V: Hypohidrosis related to administration of topiramate to children. Epilepsia (2001) 42:1363-1365.
   PubMed Web of Science ®Google Scholar
• BEN-ZEEV B, WATEMBERG N, AUGARTEN A et al.: Oligohydrosis and hyperthermia: pilot study of a novel topiramate adverse effect. J. Child Neurol. (2003) 18:254-257.
   PubMed Web of Science ®Google Scholar
• DE CAROLIS P, MAGNIFICO F, PIERANGELA G et al.: Transient hypohidrosis induced by topiramate. Epilepsia (2003) 44:974-976.
   PubMed Web of Science ®Google Scholar
• BAKER GA, CURRIE NG, LIGHT MJ, SCHNEIDERMAN JH: The effects of adjunctive topiramate therapy on seizure severity and health-related quality of life in patients with refractory epilepsy – a Canadian study. Seizure (2002) 11:6-15.
   PubMed Web of Science ®Google Scholar